Published in final edited form as:

J Heart Lung Transplant. 2018 September ; 37(9): 1131–1140. doi:10.1016/j.healun.2018.04.007.

BRONCHIOLITIS OBLITERANS SYNDROME SUSCEPTIBILITY AND THE PULMONARY MICROBIOME

Cody Schott, BA^{1,2}, S. Samuel Weigt, MD³, Benjamin A. Turturice, BS^{1,2}, Ahmed Metwally, MS⁴, John Belperio, MD³, Patricia W. Finn, MD^{1,2,*}, and David L. Perkins, MD PhD^{5,6,*}

¹Department of Medicine, Division of Pulmonary, Critical Care, Sleep, and Allergy, University of Illinois at Chicago, Chicago, IL

²Department of Microbiology and Immunology, University of Illinois at Chicago, Chicago, IL

³Department of Internal Medicine, Division of Pulmonary, Critical Care Medicine, Allergy, and Clinical Immunology, University of California at Los Angeles, Los Angeles, CA

⁴Department of Bioengineering, University of Illinois at Chicago, Chicago, IL

⁵Department of Medicine, Division of Nephrology, University of Illinois at Chicago, Chicago, IL

⁶Department of Surgery, University of Illinois at Chicago, Chicago, IL

Abstract

Background—Lung transplantation outcomes remain complicated by bronchiolitis obliterans syndrome (BOS), a major cause of mortality and re-transplantation for patients. A variety of factors linking inflammation and BOS have emerged, meriting further exploration of the microbiome as a source of inflammation. In this analysis, we determined features of the pulmonary microbiome associated with BOS susceptibility.

Methods—Bronchoalveolar lavage (BAL) samples were collected from patients (n = 25) during standard of care bronchoscopies prior to BOS onset. Microbial DNA was isolated from BAL fluid and prepared for metagenomics shotgun sequencing. Patient microbiomes were phenotyped using *k*-means clustering, and compared to determine effects on BOS-free survival.

Results—Clustering identified three microbiome phenotypes: Actinobacteria dominant (AD), mixed (M), and Proteobacteria dominant (PD). AD microbiomes, distinguished by enrichment with Gram-positive organisms, conferred reduced odds and risks for patients to develop acute

Corresponding Author: David L. Perkins MD PhD, perkinsd@uic.edu.
*shared co-last author.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest: The authors do not have any conflicts of interest to declare. All authors have read the policy on disclosure of potential conflicts of interest outlined by the **journal**. All authors have read the journal's authorship agreement, and the article has been reviewed by and approved by all named authors.

Author's contributions:

CS and DLP conceived, designed experiments, and performed experiments. Specimens and clinical data were collected by SW and JB. CS, BAT, and AM analyzed data. DLP, PWF contributed reagents and materials. CS, PWF, DLP wrote the manuscript.

rejection and BOS compared to non-AD microbiomes. These findings were independent of treatment models. Microbiome findings were correlated with BAL cell counts and polymorphonuclear cell percentages.

Conclusions—In some populations, features of the microbiome may be used to assess BOS susceptibility. Namely, a Gram-positive enriched pulmonary microbiome may predict resilience to BOS.

Keywords

Pulmonary; Transplant; Bronchiolitis Obliterans Syndrome; BOS; microbiome; bronchoalveolar lavage; metagenomic shotgun sequencing

Introduction

Outcomes for lung transplantation patients notably lag behind other solid organ transplants, with median survivals averaging approximately 5 and a half years. The development of bronchiolitis obliterans syndrome (BOS) persists as the major cause of mortality and re-transplantation for patients who survive beyond the first year¹. BOS is characterized by alloimmune, autoimmune and inflammatory reactivity leading to fibro-proliferative infiltrates in the bronchiolar tree, resulting in end-stage obstruction and parenchymal damage². Greater than 50% of lung allograft recipients develop BOS within 5 years following transplant, and greater than 75% develop BOS within 10 years¹.

Inflammation has been linked to pathogenesis of BOS and other rejection phenotypes^{3,4}, but inflammation can be influenced by a variety of factors. Acute rejection, HLA mismatching and the development of autoimmunity to collagen are direct sources of immune reactivity linked to BOS development. External mediators of inflammation are less well understood. For example, the lung's exposure to the environment can increase susceptibility to infection, which is further complicated by immunosuppression⁵. CMV, *Aspergillus*, and *Pseudomonas* infections are also associated with increased incidence of BOS^{6–8}, but contributions from the pulmonary microbiome remain poorly defined.

Host-microbe interactions are capable of modulating immune responses, inducing resilience or exacerbation of certain inflammatory and fibrotic processes^{9,10}. The lung, previously presumed sterile, exhibits a microbiome¹¹. Pulmonary dysbiosis has been associated with another fibro-proliferative pulmonary disorder, Idiopathic Pulmonary Fibrosis¹². Consistent with this observation, there are notable changes in the microbiome following lung transplantation^{13,14}, suggesting that a relationship with BOS merits further exploration.

Recent advances in the area of microbiome research have enabled improved diagnostic and analytic techniques related to the microbiome which we employ in our study¹⁵. These advances also represent new avenues to explore biomarkers and pathophysiology in BOS. Standard of care surveillance bronchoscopies provide material to investigate the effects of allograft colonization within months. In this study we analyzed whether exposure to elements of the pulmonary microbiome contribute to BOS development in lung transplant

patients. Using metagenomic shotgun sequencing of bronchoalveolar lavage (BAL) samples, we identified a pulmonary microbiome phenotype associated with resilience to BOS.

Materials and Methods

Identification of study subjects and sample acquisition

Lung transplant recipients at the University of California, Los Angeles (UCLA) were enrolled in an observational registry study that included collection of additional BAL fluid for research purposes at the time of standard of care bronchoscopies. This study was approved by the UCLA Institutional Review Board (IRB# 2515-0085). All subjects were provided written informed consent to participate in the study. This study included standardized medical record abstraction including demographic, transplantation, and outcome related variables. From this registry, 360 patients contributed 1639 samples to a biorepository. From this cohort, we established a case-control study to distinguish features between patients with early-onset BOS (within the first three years post-transplant) and BOS-free patients. BOS was defined using ISHLT criteria¹⁶. Patients without a BOS diagnosis who died before 3 years of follow up were excluded from this study. Because bacterial infections have downstream implications on the microbiome and vary in origin, patients with positive bacterial cultures were also excluded. From these criteria, 73 BOS and 85 BOS-free subjects were identified (Table 1). For study of the microbiome, 25 subjects were randomly selected, of which 10 developed early-onset BOS and 15 remained BOS-free. Because BOS was the outcome of interest and exclusion criteria included death within 3 years, death was not considered a relevant risk in study design. Patients were followed until BOS development, censor, or study end date (May 2013).

Bronchoscopies were performed as standard of care, and eligible patients were required to have had at least one bronchoscopy. Up to 3 longitudinal samples per patient were obtained. 53 total samples from 25 subjects were acquired. Sample processing and microbiome analysis were performed following subject selection was limited to those subjects.

DNA isolation, library construction, and sequencing

Microbial content was isolated from BAL fluid aliquots by centrifugation at 22,000 RPM. The resulting pellet was pre-treated with DNase, followed by lysis using lysozyme and proteinase K. DNA was isolated using the QIAamp MinElute Virus Spin Kit (Qiagen). DNA concentrations were measured using the Qubit 2.0 fluorimeter (Invitrogen). For the purposes of this study, metagenomics shotgun sequencing was used due to enhanced specificity and sensitivity for taxonomic identification¹⁷. Sequencing libraries were constructed and indexed from isolated DNA content using the Nextera XT kit (Illumina). Samples were sequenced on the Illumina MiSeq platform using a V3-600 kit (Illumina).

Taxonomic profiling

The produced metagenomic sequencing reads were processed with a custom pipeline hosted on the UIC supercomputer "Extreme". First, the sequences were quality controlled by filtering out all low-quality reads (<25 on Phred quality score), short reads (<100 bp), or any human reads. High-quality microbial short-reads were then assembled into contigs using

MetaVelvet¹⁸. For each sample, taxonomic profiles were constructed using WEVOTE¹⁹. Since WEVOTE is an ensemble classifier, we used Kraken²⁰, Clark²¹, and BLASTN²² as base classifiers for WEVOTE.

Ordination and clustering

Statistical analyses were performed using the R statistical environment (version 3.3.0)²³. Sequencing results, taxonomic annotations, and metadata were collated using the *phyloseq* package²⁴. To determine sample similarity, principle coordinates analysis (PCoA) was performed on all 53 samples using Bray-Curtis dissimilarity measures from the *vegan* package²⁵. The *k*-means method was used for clustering and defining microbiome phenotypes based on the first two axes defined from the PCoA. The amount of clusters was determined using the gap statistic method from the *cluster* package.

Survival analysis

Relationships between microbiome phenotypes and rejection outcomes were measured using odds and risk ratios calculated by the *epitools* package. Acute rejection scores were available at the time of sampling for each sample. Kaplan-Meier Survival analysis was performed using the *survival* and *survminer* packages to determine potential BOS-free survival advantages in a given microbiome phenotype. Baseline phenotypes for this analysis were microbiome phenotypes at the first sampling time point post-transplant. Cox regression models were constructed to distinguish whether the microbiome or other covariates, such as immunosuppression and prophylaxis, influenced outcomes. For Cox models, significance was determined using Fisher's exact test, and findings were reported as hazard ratios.

Enrichment testing and network analysis

Generalized linear models were constructed using the *DESeq2* package for differential abundance testing on all 53 samples²⁶. Models included cluster phenotypes and sampling timeframe to account for time-dependent associations, and used the Wald method to determine significance. Findings were reported as β (enrichment) values, and were used to identify organisms significantly enriched in given microbiome phenotypes. To determine effects of community structures in samples, co-occurrence matrices were constructed using the *spieceasi* package²⁷, and visualized using the Cytoscape program (version 3.5.1)²⁸. Enriched taxa were modeled against corresponding cytology data as clinically available using linear regression on GraphPad Prism (version 4.03).

Results

Patient characteristics

Patients were recruited and followed for at least 2 years post-transplant. Mean follow up time for early-onset BOS patients was 2.0 years and 5.4 years for BOS-free patients. At least one, and up to three BAL samples were obtained per subject (53 total samples). BOS development was analyzed as the primary outcome for this analysis, while other clinical (Table 2) and therapeutic (Table 3) features were used as secondary covariates. Our multivariate analysis showed no clinical covariates significantly correlated with BOS development (Table S1).

Ordination and clustering identify distinct microbiome profiles

Our taxonomic analysis identified 2,726 unique microbial species in the BAL samples. Taxa were agglomerated at the phylum level to analyze sample composition (Figure 1A), and PCoA was performed at the species level. Stratification of the results based on BOS development showed no significant distinction in sample microbiomes. Further analysis was performed on all sample microbiomes using *k*-means clustering. Three clusters were identified along the first two principle coordinate axes, accounting for a combined 45.9% of the variance across samples (Figure 1B). Actinobacteria dominant (AD), Mixed (M), and Proteobacteria dominant (PD) clusters were defined based on different phylum composition. Notably, the AD cluster had minimal variance along Axis 1, suggesting a well-defined phenotype, which was confirmed using the analysis of similarities (ANOSIM) technique²⁹ (Figure 1C). ANOSIM also determined that there was significant dissimilarity between the clusters ($R = 0.728$, $p = 0.001$). Prophylactic antifungal, antiviral, and antibiotic usage were not significantly associated with cluster designation (not shown). Over the course of the study, 47% of patients with more than one sample maintained the same cluster phenotype across all of their samples (Figure 1D).

Pulmonary microbiome clusters implicated in susceptibility to allograft rejection

Given the ability of microbial communities to modulate inflammation¹⁰, we assessed the relationship of the pulmonary microbiome with allograft rejection. Acute rejection scores (A, airway and B, vascular) were obtained at the time of each bronchoscopy. Although no patients suffered high grade rejection (A or B grade 3+), a link was detected between acute rejection and our microbiome phenotypes. Specifically, those patients with an AD microbiome had an odds ratio of 0.24 and risk ratio of 0.55, indicating reduced risk of developing either airway or vascular acute rejection compared to other clusters (Fisher's exact $p < 0.05$). Previous reports show that acute rejection is one of the strongest indicators of susceptibility to chronic rejection^{30,31}, and we determined odds and risk ratios linking the microbiome with BOS. To standardize the effect that microbiome exposure had on BOS, samples were divided based on time from transplantation. For samples collected within 3 months post-transplant, AD microbiomes conferred significantly reduced odds and risk for BOS development, 0.057 and 0.23 respectively (Fisher's exact $p < 0.01$). Odds and risk for BOS were not significantly affected by microbiome phenotype in samples collected beyond this initial surveillance period. Kaplan-Meier curves (Figure 2A) revealed significantly increased BOS-free survival for AD microbiomes ($n = 15$) compared to non-AD microbiomes at baseline ($n = 10$). These findings showed that the AD phenotype is associated with reduced BOS susceptibility, particularly within the first three months post-transplant.

To determine whether prophylactic or immunosuppressive treatment regimens were correlated with enhanced BOS-free survival in the AD cluster, Cox regression analysis was performed. Similar to the Kaplan-Meier model, the multivariate Cox model detected a significantly reduced hazard for individuals with an AD microbiome, independent of any covariate features (Figure 2B). No covariates were independently associated with increased or decreased risk of BOS development. Together, these data suggest that AD microbiomes

were correlated with improved outcomes in transplant patients, and associated with reduced risk of rejection.

Increased diversity and enrichment of key taxa associate with reduced incidence of rejection

To establish which features of the AD microbiome were associated with decreased susceptibility to allograft rejection, we analyzed community properties and the species and genera of the lower-respiratory tract microbiome. Alpha diversity indices showed significantly increased richness (Fisher) in the AD cluster compared to M and PD clusters (Figure 3A,B) to identify contributory organisms, linear models were developed to identify clinical features that differentiate metagenomic findings between samples. Using PERMANOVA³², clustering was the strongest differentiator ($p < 0.001$). No clinical covariates significantly differentiated features of sample microbiomes. Accordingly, AD clustering was modeled against phylum and genus level counts. Several taxa had significant differential enrichment. The top five abundant phyla and 10 top abundant genera were selected based on median abundance and their enrichment values for each cluster were plotted with confidence intervals (Figure 3C,D). Of these taxa, the Grampositive phyla Firmicutes and Actinobacteria, including genera *Propionibacterium*, *Corynebacterium*, *Staphylococcus*, and *Streptococcus*, were significantly enriched in only AD microbiomes. Proteobacteria, namely the Alphaproteobacteria *Sphingomonas*, were also significantly enriched in the AD cluster. Gram negative organisms, including the Bacteroidetes phylum, namely *Flavobacterium*, and the Gammaproteobacteria *Pseudomonas* were decreased in the AD phenotype. Alphatorqueviruses, which includes Torque Teno Virus, and *Mycoplasma*, causative agents of atypical pneumonia, were also decreased. Significantly enriched species for each cluster are shown in Table S2. These findings suggest a model where enrichment with the identified Gram-positive organisms, as well as Alphaproteobacteria, are predictive of rejection-free survival, and may contribute to host resilience against BOS development. Bacteroidetes, *Pseudomonas*, *Mycoplasma*, and Alphatorquevirus enrichment favors non-AD phenotypes, and increased BOS susceptibility.

To elucidate how the composition of the pulmonary microbiome may contribute to BOS, network analysis was performed to determine clustering coefficients and centrality measures from co-occurrence matrices (interactions were filtered for significant interactions between taxa ($p < 0.01$)). Networks for AD and non-AD microbiomes were plotted using Cytoscape, and minimal overlap between networks was observed (Figure 3E). Two distinct communities were identified in the AD cluster, with significant interactions among the core Gram-positive genera defining one of these communities. Interactions in non-AD clusters were less extensive, and centered on *Pseudomonas aeruginosa* as a hub organism. Network statistics confirm these findings; AD microbiomes had a greater clustering coefficient (0.358 to 0.248) and a greater network diameter (12 to 9) compared to non-AD samples. These network analyses indicate that the pulmonary milieu, not just individual taxa, contributes to BOS susceptibility.

Pulmonary cytology associates with microbiome findings

To establish links between features of the microbiome and host immune response factors, taxa abundance was correlated with corresponding cytology data from BAL. We hypothesized that AD-enriched taxa would display less inflammatory profiles, while AD-decreased taxa would exhibit more inflammatory properties. Using linear regression, count data from previously described organisms was modeled against bronchoalveolar cell profiles. Notably, we identified significant associations between taxa and total cell counts and polymorphonuclear cell (PMN) percentage (Figure 4). Expectedly, as AD-enriched *Propionibacterium* became more abundant, total BAL cell count decreased, suggesting a decreased inflammatory profile. These findings were reversed when analyzing AD-decreased taxa: *Flavobacterium*, *Mycoplasma*, and *Yersinia* were all significantly positively correlated with total BAL cell count. AD-enriched *Corynebacterium* had a significant negative correlation with PMN percentage, suggesting that members of the AD microbiome are inversely related to neutrophil presence in the lungs. Neutrophil-associated inflammation has been linked to BOS, and neutrophilia has been purported as a biomarker for BOS³³. Cutoffs for neutrophilia at 16% have been described³⁴. Applying this cutoff to our study, we observed that normal samples had increased abundance of *Corynebacterium* compared with PMN-high samples. These findings suggest a role for the pulmonary microbiome in shaping the inflammatory cell profile of lung transplant patients, with implications for BOS susceptibility.

Discussion

Recent studies have postulated that changes in the lower respiratory microbiome contribute to allograft physiology. To define a community of organisms associated with BOS susceptibility, we employed metagenomic shotgun sequencing on BAL samples from lung transplant patients. Cluster based phenotyping identified enrichment with the genera *Propionibacterium*, *Corynebacterium*, *Staphylococcus*, *Streptococcus*, and *Sphingomonas* to be significantly associated with improved outcomes. A similar lower airway microbiome phenotype marked by enrichment with *Propionibacterium*, *Corynebacterium*, *Staphylococcus*, and *Streptococcus* had been previously described, and was associated with reduced pulmonary inflammation³⁵. Recently, *Staphylococcus* has been linked to destructive remodeling of lung architecture in allograft recipients¹³. Those findings did not account for community interactions between organisms, which are known to modulate bacterial behavior³⁶. Whether these organisms represented reconstitution from the recipient's commensal organisms, a factor reported to contribute to BOS-free survival³⁷, remains unclear.

Our study demonstrates that AD-decreased organisms include Gram-negative populations and their enrichment lead to worse outcomes. These findings include *Flavobacterium*, and *Pseudomonas*. Interestingly, AD-decreased taxa also included Alphatorquevirus, a genus which includes Torque Teno Virus, whose abundance has been correlated with higher levels of immunosuppression in transplant recipients³⁸. *Mycoplasma*, a causative agent of atypical pneumonia, was also decreased. Conversely, the resilient AD microbiomes were significantly enriched with Gram-positive organisms. We speculate that the microbiome

influences rejection outcomes through interactions triggering innate immune mechanisms. Of those mechanisms, TLR4 signaling and bacterial lipopolysaccharide (LPS) exposure have been implicated in BOS development³⁹. Unsurprisingly, neutrophilic responses have been associated with worse outcomes in transplant patients³³. Thus, it is possible that the resilient AD phenotype promotes graft survival by reduced TLR4 signaling, thereby promoting immune tolerance. Interestingly, the sole Gram-positive AD-enriched taxa *Sphingomonas* contains glycosphingolipids in place of LPS. Likewise, our analysis of BAL cell profiles suggests that the AD microbiome associates with reduced inflammatory cell recruitment to the lung. Future studies analyzing links between the microbiome and inflammatory activity of BAL cells are warranted.

The microbiome may serve both mechanistic and diagnostic purposes. Our findings are enhanced by the sampling timeframe which occurred prior relative to BOS onset. Surveillance bronchoscopies occurred within the first year post-transplant, and then were followed for at least two years. Notably, our findings show that uncovering an AD phenotype in patients, particularly within 3 months post-transplant, confers significantly reduced odds and risk for patients to develop BOS. Based on our observation that changes in the microbiome occur prior to BOS development, microbiome profiles may serve as clinically significant biomarkers for the development of BOS. Specifically, modulating prophylactics and immunosuppression at an earlier clinical stage may improve outcomes for those susceptible to BOS.

While we differentiated outcomes in clinical subgroups following lung transplantation, the retrospective nature of our study affected experimental design considerations. Our analyses were limited by sample size, non-standardized sampling time frames for subjects, lack of environmental background, and exclusion criteria. To account for these potential confounders, differential abundance testing was applied to identify significantly enriched organisms and to limit contributions of environmental background and outlier organisms. The linear model applied to the package considered variations in sampling time of the patients, thereby negating any effect that time to surveillance bronchoscopy had on microbial enrichment. Although this study did not consider the role bacterial infections may play in BOS-related dysbiosis, such infections are already established risk factors for BOS⁴⁰. By excluding these samples, we delineate subclinical exposures priming the lung for chronic rejection.

In this study we examined whether the microbiome contributes to and may be predictive of susceptibility or resilience to BOS. We established a significant relationship between the pulmonary microbiome and BOS susceptibility. A resilient Actinobacteria dominant phenotype had significant enrichment with well characterized Gram-positive genera, and was associated with reduced inflammatory cell recruitment to the lung. Likewise, increased Alphatorquevirus and Gram-negative organisms were associated with increased inflammatory cell recruitment. These analyses suggest that modulating immunosuppression or introduction of microbiome-based therapeutics (probiotics or phages) to favor an AD phenotype may provide a novel opportunity to influence lung allograft rejection.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Support for this study was provided in part by NIH grant number F30HL137267.

References

1. Lund LH, Edwards LB, Dipchand AI, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-third Adult Heart Transplantation Report-2016; Focus Theme: Primary Diagnostic Indications for Transplant. *J Heart Lung Transplant*. 2016; 35(10):1158–1169. [PubMed: 27772668]
2. Barker AF, Bergeron A, Rom WN, Hertz MI. Obliterative bronchiolitis. *N Engl J Med*. 2014; 370(19):1820–1828. [PubMed: 24806161]
3. Weigt SS, Palchevskiy V, Belperio JA. Inflammasomes and IL-1 biology in the pathogenesis of allograft dysfunction. *J Clin Invest*. 2017; 127(6):2022–2029. [PubMed: 28569730]
4. Todd JL, Wang X, Sugimoto S, et al. Hyaluronan contributes to bronchiolitis obliterans syndrome and stimulates lung allograft rejection through activation of innate immunity. *Am J Respir Crit Care Med*. 2014; 189(5):556–566. [PubMed: 24471427]
5. Burguete SR, Maselli DJ, Fernandez JF, Levine SM. Lung transplant infection. *Respirology*. 2013; 18(1):22–38. [PubMed: 22591266]
6. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. *Am J Transplant*. 2009; 9(8):1903–1911. [PubMed: 19459819]
7. Botha P, Archer L, Anderson RL, et al. Pseudomonas aeruginosa colonization of the allograft after lung transplantation and the risk of bronchiolitis obliterans syndrome. *Transplantation*. 2008; 85(5):771–774. [PubMed: 18337673]
8. Weigt SS, Elashoff RM, Keane MP, et al. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. *Am J Transplant*. 2008; 8(7):1512–1522. [PubMed: 18513272]
9. Relman DA. The human microbiome: ecosystem resilience and health. *Nutr Rev*. 2012; 70(Suppl 1):S2–9. [PubMed: 22861804]
10. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. *Nat Rev Immunol*. 2009; 9(5):313–323. [PubMed: 19343057]
11. Dickson RP, Huffnagle GB. The Lung Microbiome: New Principles for Respiratory Bacteriology in Health and Disease. *PLoS Pathog*. 2015; 11(7):e1004923. [PubMed: 26158874]
12. Salisbury ML, Han MK, Dickson RP, Molyneaux PL. Microbiome in interstitial lung disease: from pathogenesis to treatment target. *Curr Opin Pulm Med*. 2017; 23(5):404–410. [PubMed: 28650861]
13. Mouraux S, Bernasconi E, Pattaroni C, et al. Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung. *J Allergy Clin Immunol*. 2017
14. Dickson RP, Erb-Downward JR, Freeman CM, et al. Changes in the lung microbiome following lung transplantation include the emergence of two distinct Pseudomonas species with distinct clinical associations. *PLoS One*. 2014; 9(5):e97214. [PubMed: 24831685]
15. Szafranski SP, Wos-Oxley ML, Vilchez-Vargas R, et al. High-resolution taxonomic profiling of the subgingival microbiome for biomarker discovery and periodontitis diagnosis. *Appl Environ Microbiol*. 2015; 81(3):1047–1058. [PubMed: 25452281]
16. Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. *Eur Respir J*. 2014; 44(6):1479–1503. [PubMed: 25359357]

17. Ranjan R, Rani A, Metwally A, McGee HS, Perkins DL. Analysis of the microbiome: Advantages of whole genome shotgun versus 16S amplicon sequencing. *Biochem Biophys Res Commun*. 2016; 469(4):967–977. [PubMed: 26718401]
18. Namiki T, Hachiya T, Tanaka H, Sakakibara Y. MetaVelvet: an extension of Velvet assembler to de novo metagenome assembly from short sequence reads. *Nucleic Acids Res*. 2012; 40(20):e155. [PubMed: 22821567]
19. Metwally AA, Dai Y, Finn PW, Perkins DL. WEVOTE: Weighted Voting Taxonomic Identification Method of Microbial Sequences. *PLoS One*. 2016; 11(9):e0163527. [PubMed: 27683082]
20. Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. *Genome Biol*. 2014; 15(3):R46. [PubMed: 24580807]
21. Ounit R, Wanamaker S, Close TJ, Lonardi S. CLARK: fast and accurate classification of metagenomic and genomic sequences using discriminative k-mers. *BMC Genomics*. 2015; 16:236. [PubMed: 25879410]
22. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. *J Mol Biol*. 1990; 215(3):403–410. [PubMed: 2231712]
23. R: A Language and Environment for Statistical Computing [computer program]. Version 3.3.0. Vienna, Austria: R Foundation for Statistical Computing; 2016.
24. McMurdie PJ, Holmes S. phyloseq: an R package for reproducible interactive analysis and graphics of microbiome census data. *PLoS One*. 2013; 8(4):e61217. [PubMed: 23630581]
25. Dixon P, Palmer MW. VEGAN, a package of R functions for community ecology. *Journal of Vegetation Science*. 2003; 14(6):927–930.
26. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol*. 2014; 15(12):550. [PubMed: 25516281]
27. Kurtz ZD, Muller CL, Miraldi ER, Littman DR, Blaser MJ, Bonneau RA. Sparse and compositionally robust inference of microbial ecological networks. *PLoS Comput Biol*. 2015; 11(5):e1004226. [PubMed: 25950956]
28. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome Res*. 2003; 13(11):2498–2504. [PubMed: 14597658]
29. Buttigieg PL, Ramette A. A guide to statistical analysis in microbial ecology: a community-focused, living review of multivariate data analyses. *FEMS Microbiol Ecol*. 2014; 90(3):543–550. [PubMed: 25314312]
30. Shino MY, Weigt SS, Li N, et al. Impact of Allograft Injury Time of Onset on the Development of Chronic Lung Allograft Dysfunction After Lung Transplantation. *Am J Transplant*. 2017; 17(5): 1294–1303. [PubMed: 27676455]
31. Shino MY, Weigt SS, Li N, et al. The Prognostic Importance of Bronchoalveolar Lavage Fluid CXCL9 During Minimal Acute Rejection on the Risk of Chronic Lung Allograft Dysfunction. *Am J Transplant*. 2017
32. Anderson M. A new method for non-parametric multivariate analysis of variance. *Aust Ecol*. 2001; 26:32–46.
33. Kennedy VE, Todd JL, Palmer SM. Bronchoalveolar lavage as a tool to predict, diagnose and understand bronchiolitis obliterans syndrome. *Am J Transplant*. 2013; 13(3):552–561. [PubMed: 23356456]
34. Slebos DJ, Postma DS, Koeter GH, Van Der Bij W, Boezen M, Kauffman HF. Bronchoalveolar lavage fluid characteristics in acute and chronic lung transplant rejection. *J Heart Lung Transplant*. 2004; 23(5):532–540. [PubMed: 15135367]
35. Segal LN, Alekseyenko AV, Clemente JC, et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. *Microbiome*. 2013; 1(1):19. [PubMed: 24450871]
36. Coyte KZ, Schluter J, Foster KR. The ecology of the microbiome: Networks, competition, and stability. *Science*. 2015; 350(6261):663–666. [PubMed: 26542567]
37. Willner DL, Hugenholtz P, Yerkovich ST, et al. Reestablishment of recipient-associated microbiota in the lung allograft is linked to reduced risk of bronchiolitis obliterans syndrome. *Am J Respir Crit Care Med*. 2013; 187(6):640–647. [PubMed: 23328523]

38. Gorzer I, Jaksch P, Kundi M, Seitz T, Klepetko W, Puchhammer-Stockl E. Pre-transplant plasma Torque Teno virus load and increase dynamics after lung transplantation. PLoS One. 2015; 10(3):e0122975. [PubMed: 25894323]
39. Evers A, Atanasova S, Fuchs-Moll G, et al. Adaptive and innate immune responses in a rat orthotopic lung transplant model of chronic lung allograft dysfunction. Transpl Int. 2015; 28(1): 95–107. [PubMed: 25179205]
40. Valentine VG, Gupta MR, Walker JE Jr, et al. Effect of etiology and timing of respiratory tract infections on development of bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2009; 28(2):163–169. [PubMed: 19201342]

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 1. Clustering identifies three distinct microbial communities

A) 53 Bronchoalveolar lavage samples from 25 subjects were clustered using the k -means method and characterized by dominance at the phylum level: Actinobacteria dominant (AD), mixed (M), and Proteobacteria dominant (PD) clusters. **B)** Principle coordinates analysis was performed using Bray-Curtis distances. The three clusters are identified and their 95% confidence intervals are shown. **C)** Analysis of similarities showed significant dissimilarity between groups. **D)** Subject microbiome clusters over time are plotted. Color represents final outcomes for each patient; shapes signify microbiome clusters at each sampling timepoint.

Figure 2. Microbiome clustering associates with BOS development

Outcomes related to BOS development were tracked for each patient until BOS development or censor. **A)** Kaplan-Meier analysis was used to determine the relationship between pulmonary microbiome clusters and BOS susceptibility. AD cluster patients had significantly increased BOS-Free survival compared to non-AD clusters (Log Rank Test). Censored subjects are denoted by vertical marks on associated survival curve. Numbers at risk are shown at each year. **B)** Cox Hazard Regression analysis was performed to identify whether clinical characteristics or treatment regimens influenced BOS-free survival in AD microbiome patients. The unadjusted model represents the hazard ratio of the AD

microbiome independent of other covariates. The complete model factors in all immunosuppressive and prophylactic treatments for each patient. Patients with AD microbiomes had significantly reduced hazard regardless of modeling covariates. *: $p < 0.05$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Figure 3. Diversity, enrichment models, and network data reveal key features of AD microbiomes

A) Shannon diversity and **B)** Fisher's alpha diversity indices from bronchoalveolar lavage samples are shown. Samples were grouped based on their microbiome clustering (AD: Actinobacteria dominant; M: Mixed; PD: Proteobacteria dominant). Samples counts were normalized and modeled against AD microbiomes and sampling time using the DESeq2 package in R (Bioconductor). Significance was determined using Wald's Test. **C)** The top five abundant phyla, as well as **D)** the top five abundant positively and negatively enriched genera, are shown with their enrichment (β) values. **E)** Covariance and correlation indices were calculated using the SparCC function from the SpiecEasi package on R. Co-occurrence networks for AD Cluster (left) and non-AD Cluster (right) were plotted using Cytoscape. Previously discussed genera identified are highlighted in red (enriched in AD microbiomes) and blue (decreased in AD microbiomes). Network interactions were compiled and showed minimal overlap between AD and Non-AD Cluster microbiomes. *: $p < 0.05$; ***: $p < 0.001$.

Figure 4. Metagenomic findings correlate with bronchoalveolar lavage cytology

Associated cytology findings for each sample was compiled and correlated with corresponding metagenomics data. To determine the relationship between taxa and cytology findings, linear regression was used. **A)** *Propionibacterium* was negatively correlated with total cell counts identified from BAL. **B–D)** *Flavobacterium*, *Mycoplasma*, and *Yersinia* were positively correlated with total cell counts identified from BAL. **E)** *Corynebacterium* was negatively correlated with polymorphonuclear cell percentage, and was decreased in

neutrophilic samples (**F**). For pairwise comparison, significance was determined using the Mann-Whitney U Test.*: $p < 0.05$.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1

Cohort Characteristics.

Characteristic	Eligible (n = 158)	Included (n = 25)	Not included (n = 133)
Age, mean (SD), years	57.6 (10.5)	58.8 (8.7)	57.4 (10.9)
Sex, No. (%)			
Male	89 (56)	14 (56)	75 (56)
Female	69 (44)	11 (44)	58 (44)
Pre-transplant disease, No. (%)			
Restrictive lung disease	91 (58)	16 (64)	75 (56)
COPD	49 (31)	7 (28)	42 (32)
CF/bronchiectasis	7 (4)	0	7(5)
Pulmonary hypertension	7 (4)	1 (4)	6(5)
Other	4 (3)	1 (4)	3 (2)
BOS, No. (%)	73 (46)	10 (40)	63 (47)

A description of patients meeting inclusion and exclusion criteria (see Methods) from the lung transplant registry at the University of California at Los Angeles.

RLD: Restrictive lung disease; COPD: Chronic obstructive pulmonary disease; CF: Cystic fibrosis; PH: Pulmonary hypertension; BOS: Bronchiolitis obliterans syndrome.

Table 2

Subject characteristics.

Patient	Time from transplant (days)	Follow-up (days)	Microbiome cluster	Sex	Age (years)	Pre-transplant diagnosis	(+) <i>Aspergillus</i>	Acute rejection	BOS
1	(1) 106	1,591	(1) AD	M	70	RLD	TP1	None	Free
2	(1) 85, (2) 372	2,058	(1) PD, (2) AD	M	57	RLD	None	(1) B1	Free
4	(1) 36, (2) 117, (3) 389	1,957	(1) AD, (2) M, (3) AD	F	61	COPD	TP2	(3) A1	Free
5	(1) 28, (2) 373	759	(1) AD, (2) AD	M	53	RLD	None	None	Free
6	(1) 137, (2) 375	3,087	(1) M, (2) AD	M	64	RLD	TP1	(2) A1 B1	Free
7	(1) 189, (2) 377	2,834	(1) AD, (2) AD	F	60	COPD	None	None	Free
11	(1) 36, (2) 100, (3) 274	2,927	(1) AD, (2) AD, (3) AD	F	63	RLD	None	None	Free
14	(1) 202	1,825	(1) AD	F	34	LAM	TP1	(1) A2	Free
15	(1) 36	1,203	(1) AD	M	66	COPD	None	None	Free
16	(1) 371	2,785	(1) AD	M	61	COPD	None	None	Free
19	(1) 32, (2) 95, (3) 364	2,291	(1) AD, (2) AD, (3) AD	F	58	RLD	None	None	Free
21	(1) 37, (2) 87	2,129	(1) M, (2) AD	M	69	RLD	TP2	None	Free
22	(1) 180	788	AD	F	65	COPD	None	None	Free
24	(1) 33, (2) 187	1,866	(1) AD, (2) AD	M	46	RLD	None	(1) A2 B1	Free
25	(1) 53, (2) 82	1,324	(1) AD, (2) AD	M	69	RLD	TP2	(1) A2 B1	Free
3	(1) 51, (2) 72	817	(1) PD, (2) M	F	56	COPD	TP2	(1) A2	BOS
8	(1) 74, (2) 686	739	(1) M, (2) M	F	59	COPD	TP1	(1) B1, (2) A1 B1	BOS
9	(1) 61, (2) 90, (3) 572	791	(1) M, (2) M, (3) AD	F	62	RLD	TP2	(1) A1, (3) B1	BOS
10	(1) 85, (2) 469	720	(1) M, (2) M	F	57	COPD	TP1	(1) B1, (2) A1 B1	BOS
12	(1) 33, (2) 91, (3) 410	510	(1) AD, (2) AD, (3) AD	M	62	RLD	TP2	None	BOS
13	(1) 33, (2) 173, (3) 565	630	(1) M, (2) AD, (3) AD	M	60	PH	None	(1) A2, (3) A1 B1	BOS
17	(1) 35, (2) 90, (3) 370	943	(1) PD, (2) PD, (3) AD	M	65	RLD	TP2	None	BOS
18	(1) 177	1,081	(1) AD	F	47	RLD	None	None	BOS
20	(1) 33, (2) 193, (3) 368	535	(1) AD, (2) M, (3) AD	M	60	RLD	None	None	BOS
23	(1) 31, (2) 184, (3) 311	715	(1) M, (2) M, (3) M	M	43	RLD	None	(1) A1, (2) A1	BOS

Lung transplant recipients (n = 25) underwent bronchoscopy and bronchoalveolar lavage samples were obtained. As clinically available, longitudinal samples were obtained. Clinical features at time of sampling are provided for each subject, and are denoted in the table by timepoint numbers for respective subjects. Only positive acute rejection (both A- and B- scores) are shown. Subjects were followed until BOS development or censor.

LAM: Lymphangioleiomyomatosis.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 3

Treatment Regimens

Patient	Induction	Maintenance	Prophylactics	Other	BOS
1	Basiliximab	Tacrolimus, mycophenolate, prednisone	Valganciclovir		Free
2	ATG + PLEX	Tacrolimus, mycophenolate, prednisone	Bactrim, acyclovir		Free
4	ATG	Tacrolimus, mycophenolate (TP1, TP2) prednisone	Bactrim, valganciclovir, voriconazole		Free
5	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir, itraconazole (TP1), voriconazole (TP2)		Free
6	ATG	Tacrolimus, mycophenolate, prednisone	None		Free
7	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir		Free
11	Basiliximab	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir		Free
14	ATG	Tacrolimus, sirolimus, prednisone	Bactrim, valganciclovir		Free
15	Basiliximab	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir, CytoGam, ^b voriconazole, isoniazid		Free
16	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, acyclovir, voriconazole		Free
19	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim		Free
21	Basiliximab	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir		Free
22	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, acyclovir, fluconazole		Free
24	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir		Free
25	Basiliximab	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir		Free
3	ATG	Tacrolimus, mycophenolate, prednisone	ganciclovir, itraconazole	(TP2) Meropenem, ciprofloxacin	BOS
8	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, ganciclovir, itraconazole	(TP2) cefepime, tobramycin	BOS
9	Basiliximab	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir, itraconazole (TP1, TP2)	(TP2) azithromycin, (TP3) minocycline	BOS
10	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir, voriconazole (TP1)		BOS
12	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir, posaconazole (TP3)		BOS
13	ATG	Tacrolimus, mycophenolate (TP1, TP3), sirolimus (TP2), prednisone	Bactrim, valganciclovir, voriconazole (TP1), fluconazole (TP2, TP3)		BOS
17	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir (TP1), ganciclovir (TP2), itraconazole (TP2)	(TP2) colistin	BOS
18	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir, voriconazole		BOS
20	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir, isoniazid, voriconazole (TP2, TP3)		BOS
23	ATG	Tacrolimus, mycophenolate, prednisone	Bactrim, valganciclovir		BOS

Immunosuppression induction, immunosuppressive therapy, and prophylactic regimens are provided for each subject. Timepoint specific changes to treatment regimens are denoted by timepoint number for each subject.

ATG: Anti-thymocyte globulin; PLEX: Plasma exchange.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript